GTBP - GT Biopharma Inc Company Long-Term Liabilities

Public company logo of GT Biopharma Inc (GTBP)

GT Biopharma, Inc. (GTBP) is developing innovative TriKE drugs for the targeted destruction of tumors, aiming for global leadership in the oncohematology segment through the expansion of clinical trials. This chart illustrates the price action of the asset with a debt metric of 0.00. The business's financial stability relies on medical test results and external investments, as it currently has no proprietary sales.

gtbiopharma.com (GTBP) Company Long-Term Debt: for the period 07/04/2022 - 10/31/2026

GT Biopharma Corp (GTBP) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price gtbiopharma.com|GTBP - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation GT Biopharma|GTBP - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share GT Biopharma|GTBP - Company Book Value|Market Value to Book Value gtbiopharma.com|GTBP - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio GT Biopharma, Inc.|GTBP - Long-Term Debt to Capital|Short-Term Debt to Equity GT Biopharma Corporation|GTBP - Company Debts|Debt to Book Capitalization Ratio GT Biopharma|GTBP - Company Long-Term Debt|Short-Term Debt GT Biopharma|Immediate Liquidity gtbiopharma.com
- earnings and market multiples details:
GTBP - Net Profit
Analysis of all company metrics:gtbiopharma.com (GTBP)
Brand item of GT Biopharma Corporation

Asset managers require an accurate assessment of an issuer's long-term solvency to minimize risks. This indicator captures total liabilities with maturities exceeding one year, determining the level of debt load. Analyzing the firm's long-term borrowings allows for the identification of hidden liquidity threats through loan service dynamics. For GT Biopharma, Inc. (GTBP), such investments are critical for developing costly cold chains. This ensures the preservation of oncology drugs and stable business margins.

Competitors of GT Biopharma, Inc. (GTBP)

TGTX: Company Long-Term Indebtedness|Arcellx, Inc. - Company Long-Term Debts|Disc Medicine Inc (IRON) - Company Long-Term Liabilities|SNDX: Company Long-Term Debts|Long-Term Debt Kura (KURA)|Company Long-Term Debt ADC Therapeutics|FHTX: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities VOR (Vor Biopharma)|NKTX (nkartatx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts COEP (Coeptis Therapeutics, Inc.)|Actinium Corp - Company Long-Term Debt|ESLA - Company Long-Term Debt|CASI: Company Long-Term Debt|markertherapeutics.com (MRKR) - Company Long-Term Debt|Long-Term Debt IN8bio Inc. (INAB)|Company Long-Term Debt Eterna Therapeutics, Inc.|Long-Term Debt Aptose APTO|Company Long-Term Debts BPTH|meipharma.com - Company Long-Term Indebtedness|Company Long-Term Debts VINC (Vincerx Pharma)